Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995078 | 0.91 | HRH3 (0.45) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL13161940 | 0.82 | CHRM4 (0.43) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL933211 | 0.78 | CHRM4 (0.40) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL22683412 | 0.74 | LRRK2 (0.35) | LRRK2 | |
| SCHEMBL12929421 | 0.73 | LRRK2 (0.48) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL20145042 | 0.71 | PDE3B (0.47) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL20898844 | 0.71 | PDE3B (0.37) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL189065 | 0.70 | HRH3 (0.53) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL20158541 | 0.70 | PIK3CD (0.40) | HRH3PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL19764133 | 0.69 | HRH3 (0.44) | CHRM4CHRM5CHRM1CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072890-B1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI PHARMA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3072890-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI Pharma, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-8486939-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2532659-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | Pathway Therapeutics, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2451802-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | Pathway Therapeutics, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005119-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | TYMP, TYMS, CCNI | CHRM4 4849/4885CHRM5 4754/4885CHRM1 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.